Autism spectrum disorders (ASD) comprise a group of disorders characterized by impairments in socio-communicative skills and restrictive and stereotyped behaviours and interests. Mild, subclinical forms of autistic behaviour, however, also occur in the normal population. With an estimated prevalence of about one percent, the disorder affects about 3 million people across the EU. The current understanding of the pathophysiology of autistic disorders is still insufficient and up to now there are no effective pharmacological treatments for the core symptoms of ASD. The main focus of the research group is to investigate how autistic symptoms manifest on a biological, cognitive and behavioral level in autistic and non-autistic children and adolescents. In addition, we are investigating new psychotherapeutic and pharmacological interventions for ASD and the potential for early detection and intervention of ASD from the age of 12 months.
ASD-net: Oxytocin-induced enhancement of Social Skills Training in ASD: a randomised placebo-controlled multicenter trial (funded by BMBF).
ASDEU: Epidemiology of Autistic Disorders in Europe (Multicentre study, cooperation with the Medical University of Vienna, funded by the EU)
Volitional modification of brain activity in adolescents with ASD - a slow cortical potential neurofeedback study (study in cooperation with Dr. Lilian Konicar (PI) Medical University of Vienna, funded by FWF
Early Childhood Development in Children at Risk for Autism Spectrum Disorder - a Longitudinal Study with infants and high risk siblings (funded by DFG)
EVAS: Early, valid and reliable Screening in Autism Spectrum Disorders (funded by the Innovationsfond)